Company profile
Alaunos Therapeutics, Inc.
NASDAQ: TCRT · Healthcare · Biotechnology
#1141 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
33DFH 25DQ 51GM 15SS 39
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ workforce scale, operating margin
Methodology →Revenue TTM
$3.0k
Rev growth YoY (TTM)
-50.0%
Net income (FY)
-$4.2M
Employees
1
as of 2026-08-23
Market cap
$4.3M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$5.0k$5.0k2025
Net income-$4.2M-$4.2M2025
Operating income-$4.2M-$4.2M2025
Total assets$3.0M$3.0M2025
Liabilities$813.0k$813.0k2025
Equity$2.2M$2.2M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Alaunos Therapeutics, Inc.’s revenue?
Alaunos Therapeutics, Inc. booked $5.0k in FY2025 revenue, contracting 50% year over year — slower than 81% of Healthcare companies we track, at a -83520.0% net margin.
Peers · Healthcare
Kaya Holdings, Inc.——Aspire Biopharma Holdings, Inc.17DCreative Medical Technology Holdings, Inc.46DOne World Products, Inc.——Pharmagen, Inc.——HeartSciences Inc.——Neighbors
Harris →Key facts
CEOHolger Weis
SectorHealthcare
IndustryBiotechnology
HeadquartersHouston, TX
ExchangeNASDAQ: TCRT
Employees1
IPO date2005-08-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.